SCHEMBL30748903

SCHEMBL30748903

COc1cc(F)ccc1N1C(=O)C(C)(C)c2c(Cl)nc(Cl)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.35
HSD11B1 P28845 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTR7 P34969 3/20 0.34
SCN9A Q15858 1/20 0.34
MAPK14 Q16539 4/20 0.33
G6PD P11413 1/20 0.33
TLR9 Q9NR96 1/20 0.33
NPBWR1 P48145 1/20 0.33
MCHR1 Q99705 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
TP53 P04637 1/20 0.33
MDM2 Q00987 1/20 0.33
MAPK11 Q15759 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749097 0.79 MAPT (0.44) ALOX15
SCHEMBL30748983 0.79 PGR (0.37) ALOX15HSD11B1MAPK14
SCHEMBL30748786 0.78 PSEN1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30748904 0.68 RAD51 (0.42)
SCHEMBL30749007 0.68 ELANE (0.44)
SCHEMBL30748931 0.67 PDE3B (0.41) MAPK14MAPK11
SCHEMBL25343730 0.66 SLC2A1 (0.44) NPBWR1MCHR1TP53
SCHEMBL25343398 0.60 SLC2A1 (0.42) SCN9ANPBWR1MCHR1
SCHEMBL1471636 0.59 G6PD (0.41) HTR7G6PDTLR9
SCHEMBL1947184 0.59 SMN1; SMN2 (0.42) CYP3A4CYP2C19HTR7NPBWR1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ALOX15 74/4885HSD11B1 495/4885CYP3A4 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.